EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

AI BRIEFING

• ⬤ EUDA Health Holdings Limited's subcompany Shenzhen Inno Immune Co., Ltd. receives approval under 2025 Shenzhen Key Industry R&D Program for TCR-T cell therapy development.
• ⬤ The approval was granted by the Shenzhen government.
• ⬤ EUDA Health Holdings Limited will benefit from the support of the Shenzhen government for its TCR-T cell therapy development.